NEW YORK (360Dx) – Beckman Coulter today announced it received CE marking for its high-sensitivity troponin (hsTnI) assay.
The Access hsTnI assay is to aid in diagnosing myocardial infarction in patients presenting with chest pains or other ischemic symptoms. Beckman Coulter Diagnostics Vice President and CMO Michael Samoszuk noted in a statement that the new assay provides greater precision at very low levels of troponin, giving clinicians "greater confidence in interpreting test results from patients seeking emergency care due to chest pain."
Beckman Coulter added that the assay will enable hospitals to develop fast-track protocols, leading to early discharge for patients with suspected myocardial infarction. The assay has "excellent low-end sensitivity," according to the company, and can detect small differences in the cardiac troponin I levels over time.
The Access hsTnI assay can be used on the Access 2, DxI, and the entire Beckman Coulter line of Access immunoassay systems.